Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Autolus Therapeutics plc
Autolus Therapeutics plc News
Autolus Therapeutics plc Quantitative Score
About Autolus Therapeutics plc
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma. It also focuses on developing AUTO5, a hematological product candidate, which is in preclinical development. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.
Autolus Therapeutics plc Earnings & Revenue
Autolus Therapeutics plc Financials
Table Compare
Compare AUTL metrics with: | |||
|---|---|---|---|
Earnings & Growth | AUTL | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | AUTL | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | AUTL | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | AUTL | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Autolus Therapeutics plc Income
Autolus Therapeutics plc Balance Sheet
Autolus Therapeutics plc Cash Flow
Autolus Therapeutics plc Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Buy |
| Return on Equity | Strong Sell |
| Return on Assets | Strong Sell |
| Debt/Equity Ratio | Sell |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Neutral |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Autolus Therapeutics plc Valuation
Project future cash flows and get the intrinsic value per share.
Historical Market Cap
Shares Outstanding
Autolus Therapeutics plc Executives
| Name | Role |
|---|---|
| Dr. Christian Martin Itin Ph.D. | Chief Executive Officer & Director |
| Dr. Christopher Williams | Chief Business Officer |
| Mr. David Brochu | Senior Vice President & Chief Technical Officer |
| Mr. Robert F. Dolski | Senior Vice President, Chief Financial Officer & Principal Accounting Officer |
| Mr. Christopher Vann | Senior Vice President & Chief Operating Officer |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Dr. Christian Martin Itin Ph.D. | Chief Executive Officer & Director | 1964 | 2.55M | |
| Dr. Christopher Williams | Chief Business Officer | 1980 | -- | |
| Mr. David Brochu | Senior Vice President & Chief Technical Officer | Male | 1956 | -- |
| Mr. Robert F. Dolski | Senior Vice President, Chief Financial Officer & Principal Accounting Officer | Male | 1971 | -- |
| Mr. Christopher Vann | Senior Vice President & Chief Operating Officer | Male | 1965 | -- |